A double-blind, double-dummy, randomized, controlled study of entecavir versus lamivudine for treatment of chronic hepatitis B [in Chinese]

Clinical Immunology Research Center, Shanghai Jing An Qu Central Hospital, Shanghai 200040, China.
Zhonghua nei ke za zhi [Chinese journal of internal medicine] 11/2006; 45(11):891-5.
Source: PubMed


This study was to evaluate the antiviral efficacy and safety in nucleoside naive Chinese patients with chronic hepatitis B (CHB) treated with entecavir (ETV) or lamivadine (LVD).
The trial was a randomized, double-blind, double-dummy and control design. 519 nucleoside naive CHB patients were treated with daily dose of ETV 0.5 mg (258 patients) or LVD 100 mg (261 patients) for at least 52 weeks. The primary endpoint was a composite endpoint of HBV DNA < 0.7 MEq/ml by bDNA assay and ALT < 1.25 x ULN at week 48. HBV DNA levels were also measured by the Roche Cobas Amplicor(TM) PCR assay at weeks 12, 24, 36 and 48. Clinical and laboratory adverse events were recorded every 4 weeks.
Baseline characteristics were well balanced between treatment groups. The primary end point were achieved in 90% of ETV treated patients versus 69% of LVD treated patients (P < 0.0001). The mean HBV DNA level decreased 5.9 lg copies/ml (by PCR assay) from baseline in ETV group versus 4.3 lg copies/ml in LVD group (P < 0.0001). The serum HBV DNA become undetectable (< 300 copies/ml by PCR) in 76% of ETV group versus 43% of LVD group (P < 0.0001). The normalization of ALT were 90% in ETV group versus 78% in LVD group (P = 0.0003). The difference of HBeAg seroconversion rates between this 2 groups (15% vs 18%) at week 48 was no statistically significant. The overall incidence of adverse events (AEs) was comparable: 60% of ETV patients and 56% of LVD patients reported AEs; and 3% of ETV patients and 5% of LVD patients reported serious AEs.
ETV achieves better virologic and biochemical improvements in nucleoside-naive patients with CHB while the safety profile is comparable to LVD.

5 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic hepatitis B and its life-threatening sequelae are highly prevalent in China. There is a need for effective new therapies to suppress hepatitis B virus (HBV) replication and ameliorate liver disease. In this study, we compared the efficacy of telbivudine, a nucleoside analogue, with lamivudine in Chinese patients. In this phase III, double-blind, multicenter trial conducted in China, 332 patients with compensated hepatitis B e antigen (HBeAg)-positive or HBeAg-negative chronic hepatitis B were randomly assigned to treatment with 600 mg of telbivudine or 100 mg of lamivudine daily for 104 weeks. The primary efficacy endpoint was reduction in serum HBV DNA levels at week 52 of treatment. Secondary endpoints included clearance of HBV DNA to undetectable levels, HBeAg loss and seroconversion, therapeutic response, and alanine aminotransferase (ALT) normalization. Viral resistance and safety were assessed. At week 52, among 290 HBeAg-positive patients, mean reductions of serum HBV DNA were significantly greater in telbivudine recipients than lamivudine recipients (6.3 log(10) versus 5.5 log(10), P < 0.001), and HBV DNA was polymerase chain reaction-negative in significantly more telbivudine recipients than lamivudine recipients (67% versus 38%, P < 0.001). ALT normalization (87% versus 75%, P = 0.007), therapeutic response (85% versus 62%, P = 0.001), and HBeAg loss (31% versus 20%, P = 0.047) were also significantly more common in the telbivudine group. Treatment effects showed similar patterns in the smaller HBeAg-negative group (n = 42). Viral resistance in telbivudine recipients was approximately half that observed with lamivudine; however, this difference was not statistically significant. Clinical adverse events were similar in the two treatment groups. CONCLUSION: In Chinese patients with chronic hepatitis B, telbivudine treatment for 52 weeks provided greater antiviral and clinical efficacy than lamivudine, with less resistance.
    Full-text · Article · Feb 2007 · Hepatology
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Forty years ago in 1967, Professor Blumberg discovered the Australian Antigen, later known as the hepatitis B surface antigen, and was awarded the Nobel Prize. This discovery enables the diagnosis of hepatitis B virus (HBV) infection and defines its epidemiology. Viral hepatitis B infection affects global health situation, and chronic hepatitis B (CHB) is particularly serious in the Asia-Pacific region. HBV vaccines created the first breakthrough in HBV prevention. Through universal HBV vaccination program for the newborns, promoted since the mid-1980s, the main route that perpetuates chronic infection from mother to child is curbed. Most children and young adults now have immunity against HBV infection. The next breakthrough comes with therapy for CHB. This prevents progression to cirrhosis and hepatocellular carcinoma. Standard interferon therapy with modest efficacy has been largely replaced by therapy with nuclos(t)ide analogues or pegylated interferons alfa-2a and -2b. Lamivudine was approved by the FDA USA in 1998, followed by adefovir dipivoxil in 2002, entecavir in 2005, and telbivudine in 2006. Clevudine, tenofovir, and many promising candidates are in different stages of development and clinical trial. This paper critically reviews recent data published or presented since the APASL Consensus and Guideline Update of 2005. Clinical efficacy mostly in patients with raised serum alanine aminotransferase will be analyzed.
    Full-text · Article · Jul 2008 · Hepatology International
  • [Show abstract] [Hide abstract]
    ABSTRACT: AIM: The evaluate the efficacy of entecavir (ETV) in treating non-Hodgkin's lymphoma-associated (NHL) chronic hepatitis B reactivation. METHODS: Clinical data of NHL patients with HBV reactivation were analyzed retrospectively. Thirty-four patients were assigned to 2 groups, of which, group A (n = 18) was treated with ETV 1.0 mg/d and group B (n = 16) was treated with ETV 0.5 mg/d. All patients were followed-up for 24 wk. Disease evolution, incidence of interrupting chemotherapy, mortality, liver function, adverse events and clinical outcome were closely monitored. Quantitative analysis of serum HBV-DNA using real-time PCR was performed at week 2, 4, 8, 12, 24 after treatment respectively. Serum HBV marker was investigated at week 12 after anti-virus treatment. RESULTS: After 24 weeks' therapy, the incidences of chemotherapy on schedule and interrupting chemotherapy between group A and group B showed statistically significant difference (χ2 = 7.438, 4.636; P = 0.006, 0.031); while the hepatitis-related mortality rate and fatality rate between the two groups showed no significant difference. At week 2, the mean HBV DNA level decreased in both groups, lower in group A (t = 15.724, P = 0.000). At week 4, 8, 12, HBV DNA level continuously decreased, especially in group A. Serum ALT levels were markedly reduced in both groups, especially in group A. Each group had one case of adverse events. CONCLUSION: ETV at a dose of 1.0 mg shows a good prospect in antiviral therapy for NHL-associated hepatitis B virus reactivation.
    No preview · Article · Nov 2008 · World Chinese Journal of Digestology
Show more